These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 9673398)
1. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines. Pihie AH; Stanslas J; Din LB Anticancer Res; 1998; 18(3A):1739-43. PubMed ID: 9673398 [TBL] [Abstract][Full Text] [Related]
2. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Hawariah A; Stanslas J Anticancer Res; 1998; 18(6A):4383-6. PubMed ID: 9891496 [TBL] [Abstract][Full Text] [Related]
3. Antiestrogenic effects of Z-1, 1-dichloro-2,3 diphenyl-2-(4-methoxyphenyl)cyclopropane(5a) on human breast cancer cells in culture. Jain PT; Pento JT; Magarian RA Anticancer Res; 1992; 12(3):585-90. PubMed ID: 1622114 [TBL] [Abstract][Full Text] [Related]
4. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines]. Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630 [TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Reddel RR; Murphy LC; Hall RE; Sutherland RL Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620 [TBL] [Abstract][Full Text] [Related]
6. Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells. Liu ZJ; Zhu BT J Steroid Biochem Mol Biol; 2004 Mar; 88(3):265-75. PubMed ID: 15120420 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Strobl JS; Kirkwood KL; Lantz TK; Lewine MA; Peterson VA; Worley JF Cancer Res; 1990 Sep; 50(17):5399-405. PubMed ID: 2386945 [TBL] [Abstract][Full Text] [Related]
8. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin. ter Haar E; Hamel E; Balachandran R; Day BW Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity. Murphy CS; Parker CJ; McCague R; Jordan VC Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879 [TBL] [Abstract][Full Text] [Related]
10. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells. Reiner GC; Katzenellenbogen BS Cancer Res; 1986 Mar; 46(3):1124-31. PubMed ID: 3943090 [TBL] [Abstract][Full Text] [Related]
11. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. Strobl JS; Peterson VA J Pharmacol Exp Ther; 1992 Oct; 263(1):186-93. PubMed ID: 1403784 [TBL] [Abstract][Full Text] [Related]
13. Dissociation of estrogenic and cytotoxic properties of an estrogen receptor-binding platinum complex in human breast cancer cell lines. Otto AM; Faderl M; Schönenberger H Cancer Res; 1991 Jun; 51(12):3217-23. PubMed ID: 2039997 [TBL] [Abstract][Full Text] [Related]
14. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines. ter Haar E; Day BW Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221 [TBL] [Abstract][Full Text] [Related]
15. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells. Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807 [TBL] [Abstract][Full Text] [Related]
16. Growth factors and chemotherapeutic modulation of breast cancer cells. Ciftci K; Su J; Trovitch PB J Pharm Pharmacol; 2003 Aug; 55(8):1135-41. PubMed ID: 12956904 [TBL] [Abstract][Full Text] [Related]
17. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Chan VS; Ho GH Clin Cancer Res; 1999 Feb; 5(2):395-403. PubMed ID: 10037189 [TBL] [Abstract][Full Text] [Related]
18. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885 [TBL] [Abstract][Full Text] [Related]
19. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA; Oza BP; Colomer R; Lupu R Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863 [TBL] [Abstract][Full Text] [Related]
20. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen. Morrissey JJ; Raney S Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]